Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging (Q36675078)

15 August 2017

1 reference

title

Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging (English)

1 reference

15 August 2017

1 reference

Kokichi Sugano

1

1 reference

PubMed ID

17149381

15 August 2017

Tadao Kakizoe

series ordinal

2

1 reference

PubMed ID

17149381

15 August 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

15 August 2017

Nature Reviews Urology

1 reference

15 August 2017

3

1 reference

15 August 2017

12

1 reference

15 August 2017

642-652

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpuro0649

15 August 2017

0 references

cites work

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

Retinoblastoma gene mutations in primary human bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

Methylation of the E-cadherin gene in bladder neoplasia and in normal urothelial epithelium from elderly individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

Factors affecting recurrence and progression in superficial bladder tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

What we could do now: molecular pathology of bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Mechanism of activation of a human oncogene

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

FrequentFGFR3mutations in urothelial papilloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Identification of p53 gene mutations in bladder cancers and urine samples

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Accumulation of nuclear p53 and tumor progression in bladder cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Altered patterns of MDM2 and TP53 expression in human bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Altered Expression of Retinoblastoma Protein and Known Prognostic Variables in Locally Advanced Bladder Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Genetic alterations in bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Allelic loss on chromosome 9 in bladder cancer tissues and urine samples detected by blunt-end single-strand DNA conformation polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Correlation of the cell surface antigens with stage and grade in cancer of the bladder

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Immunologic indicators of prognosis in bladder cancer: the importance of cell surface antigens

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Diagnosis of bladder cancer by analysis of the allelic loss of the p53 gene in urine samples using blunt-end single-strand conformation polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Molecular followup of newly diagnosed bladder cancer using urine samples

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Cancer epigenetics comes of age

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Amplification/overexpression of a mitotic kinase gene in human bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Centrosome hyperamplification predicts progression and tumor recurrence in bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Allelic imbalances in human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism arrays

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Bladder cancer stage and outcome by array-based comparative genomic hybridization

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Profiling bladder cancer using targeted antibody arrays

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Biomarkers in cancer staging, prognosis and treatment selection

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0649

7 January 2021

Identifiers

DOI

10.1038/NCPURO0649

1 reference

15 August 2017

1 reference

PubMed ID

17149381